MYH14 and hypertrophic cardiomyopathy: <h4>Background</h4>Mavacamten is the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addressing hypercontractility and left ventricular outflow tract (LVOT) obstruction.<h4>Objectives</h4>This study evaluates left ventricular performance by non-invasive measurements of pressure-strain loops in patients treated with Mavacamten.<h4>Methods</h4>In 36 symptomatic oHCM patients, pressure-strain analysis was performed prior to 3 and 12 months after Mavacamten therapy.